Zhejiang Hisoar Pharmaceutical Reports Third Quarter 2024 Earnings

Simply Wall St

Published October 31, 2024

Zhejiang Hisoar Pharmaceutical (SZSE:002099) Third Quarter 2024 Results

Key Financial Results

Revenue: CN¥405.6m (down 16% from 3Q 2023).
Net loss: CN¥26.1m (loss narrowed by 55% from 3Q 2023).

SZSE:002099 Earnings and Revenue History October 31st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Zhejiang Hisoar Pharmaceutical's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with Zhejiang Hisoar Pharmaceutical.

Valuation is complex, but we're here to simplify it.

Discover if Zhejiang Hisoar Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.